Literature DB >> 23879201

Recent improvement in survival of patients with multiple myeloma: variation by ethnicity.

Dianne Pulte1, Maria Theresa Redaniel, Hermann Brenner, Lina Jansen, Mona Jeffreys.   

Abstract

Abstract Survival for patients with multiple myeloma has increased during the first decade of the 21st century. However, it is unknown whether the improvements in survival have extended equally in all ethnic groups. Using data from the United States Surveillance, Epidemiology and End Results Program, we assessed trends in survival and disease-related mortality for patients with myeloma by ethnic group, including non-Hispanic whites (nHw), African-Americans (AA), Hispanics and people of Asian and Pacific Islander descent (API) from 1998-2001 to 2006-2009. Overall, age adjusted 5-year relative survival increased, from 35.6% in 1998-2001 to 44% in 2006-2009. The greatest improvements were observed for patients aged 15-49, for whom survival increased by + 16.8% units for nHw and + 14.4% units for AA, whereas improvement was less pronounced and not statistically significant in Hispanics and API. Excess mortality hazard ratios were 1.20 (95% confidence interval [CI]: 1.09-1.33) for AA and 1.25 (95% CI: 1.11-1.41) for Hispanics compared to nHw in 2006-2009. Although survival increased greatly for nHw with myeloma between 1998-2001 and 2006-2009, smaller increases were observed for people of other ethnic groups. Persistent excess mortality was seen for AA and Hispanic patients with myeloma. Ethnic inequalities persisted or even increased from earlier periods to 2006-2009. The results suggest that ethnic minorities may not have benefited from newer treatments to the same extent as nHw patients have.

Entities:  

Mesh:

Year:  2013        PMID: 23879201     DOI: 10.3109/10428194.2013.827188

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  34 in total

1.  Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity.

Authors:  Maira A Castañeda-Avila; Bill M Jesdale; Ariel Beccia; Ganga S Bey; Mara M Epstein
Journal:  Cancer Causes Control       Date:  2021-06-05       Impact factor: 2.506

Review 2.  Persistent Disparities in Adult Hematopoietic Cell Transplantation.

Authors:  David G Crockett; Fausto R Loberiza
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

3.  With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.

Authors:  Nathanael R Fillmore; Sarvari V Yellapragada; Chizoba Ifeorah; Ansh Mehta; Diana Cirstea; Paul S White; Gustavo Rivero; Andrew Zimolzak; Saiju Pyarajan; Nhan Do; Mary Brophy; Nikhil C Munshi
Journal:  Blood       Date:  2019-04-19       Impact factor: 22.113

4.  Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore.

Authors:  M B Abid; D Christopher; M A Abid; M L Poon; L K Tan; L P Koh; W J Chng
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

5.  Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.

Authors:  Janick Weberpals; Dianne Pulte; Lina Jansen; Sabine Luttmann; Bernd Holleczek; Alice Nennecke; Meike Ressing; Alexander Katalinic; Maximilian Merz; Hermann Brenner
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

Review 6.  Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Authors:  Sikander Ailawadhi; Kirtipal Bhatia; Sonikpreet Aulakh; Zahara Meghji; Asher Chanan-Khan
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

7.  Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications.

Authors:  E Dianne Pulte; Lei Nie; Nicole Gormley; Kirsten B Goldberg; Amy McKee; Ann Farrell; Richard Pazdur
Journal:  Blood Adv       Date:  2018-01-23

8.  Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.

Authors:  Luciano J Costa; Ilene K Brill; James Omel; Kelly Godby; Shaji K Kumar; Elizabeth E Brown
Journal:  Blood Adv       Date:  2017-01-04

9.  Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.

Authors:  Smith Giri; Scott F Huntington; Rong Wang; Amer M Zeidan; Nikolai Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff; Natalia Neparidze
Journal:  Blood Adv       Date:  2020-05-26

10.  Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.

Authors:  Jeffrey R Schriber; Parameswaran N Hari; Kwang Woo Ahn; Mingwei Fei; Luciano J Costa; Mohamad A Kharfan-Dabaja; Miguel Angel-Diaz; Robert P Gale; Siddharatha Ganguly; Saulius K Girnius; Shahrukh Hashmi; Attaphol Pawarode; David H Vesole; Peter H Wiernik; Baldeep M Wirk; David I Marks; Taiga Nishihori; Richard F Olsson; Saad Z Usmani; Tomer M Mark; Yago L Nieto; Anita D'Souza
Journal:  Cancer       Date:  2017-05-04       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.